NMTR - NMTR STOCK NEWS

9 Meters Biopharma (NASDAQ:NMTR) announced significant preclinical findings on glucose-dependent insulinotropic polypeptide (GIP) monoclonal antibodies (mAbs) at the ACG 2022 Annual Scientific Meeting. The research indicates that these mAbs can prevent and treat obesity in animal models. A poster presentation received an Outstanding Research Award, highlighting the success of its projects. The company is advancing NM-136, an anti-GIP hu-mAb, targeting obesity disorders, with plans to submit an IND application next year. These developments reflect promising progress in combating obesity.

RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced two poster presentations at the ACG 2022 Annual Scientific Meeting scheduled from October 21-26 in Charlotte, NC. The posters will showcase preclinical data on humanized monoclonal antibodies targeting glucose-dependent insulinotropic polypeptide (GIP). The presentations are set for October 23 from 5:00 PM to 7:00 PM ET. 9 Meters is also developing NM-136, an anti-GIP hu-mAb for obesity disorders, as part of its IND-enabling program.

9 Meters Biopharma (NASDAQ:NMTR) has announced a 1-for-20 reverse stock split effective October 17, 2022, at 5:00 PM ET, aimed at compliance with Nasdaq's minimum bid price requirement. The number of shares will reduce from 259 million to approximately 12.9 million. Trading under the adjusted basis will begin on October 18, 2022. The reverse split affects all shareholders uniformly, and no fractional shares will be issued. The company continues to develop treatments for rare digestive diseases and has undergone this split as a strategic move for future compliance and growth.

9 Meters Biopharma announced positive outcomes from its Phase 2 VIBRANT study of vurolenatide, showing a 30% reduction in total stool output (TSO) for the 50 mg dosing arm compared to a 32% increase for placebo, resulting in a 62% relative reduction. Following a successful End-of-Phase 2 meeting with the FDA, the company plans to submit a Phase 3 protocol and is preparing for trial initiation. The study included multiple dosing arms and highlighted vurolenatide's potential to reduce parenteral nutrition needs among patients with short bowel syndrome.

9 Meters Biopharma (NASDAQ:NMTR) announced that CEO John Temperato will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. The presentation will be available via webcast starting September 12 at 7:00 AM ET. Focus will be on the company’s pipeline, particularly vurolenatide, a long-acting GLP-1 agonist for short bowel syndrome, which recently showed positive Phase 2 study results. Investors can also schedule one-on-one meetings with management during the event.

RALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma (NASDAQ:NMTR) will participate in the 44^th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress from September 3-6, 2022, in Vienna. The company will exhibit at booth #9, where representatives will discuss their product pipeline, focusing on vurolenatide for short bowel syndrome (SBS). Recently, positive Phase 2 results for vurolenatide were reported. The company aims to connect with healthcare professionals and share insights on clinical nutrition and GI disorders.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its participation in Citi's 17th Annual BioPharma Conference on September 8, 2022, in Boston. The company will engage in one-on-one meetings with investors to discuss its pipeline, notably vurolenatide, a GLP-1 agonist for short bowel syndrome, which recently reported positive Phase 2 study results. The company is focused on developing treatments for rare digestive diseases and has multiple near clinical-stage assets.

9 Meters Biopharma announced positive preliminary results from its Phase 2 VIBRANT study of vurolenatide for short bowel syndrome, indicating safety and efficacy. An End-of-Phase 2 meeting with the FDA is on schedule for Q3 2022. The company reported a cash balance of $29.5 million as of June 30, enhanced by an additional $20 million from debt financing, extending its cash runway into Q4 2023. However, the development of larazotide for celiac disease is being discontinued after an interim analysis did not support its continuation.

9 Meters Biopharma (NASDAQ:NMTR) announced participation in the William Blair Biotech Focus Conference on July 12-13, 2022, in New York City. CEO John Temperato will engage in a fireside chat, with the session available on-demand starting July 11, 2022. The presentation will spotlight 9 Meters' pipeline, particularly vurolenatide, a long-acting GLP-1 agonist for short bowel syndrome, which recently showed positive Phase 2 results. A Phase 3 study is planned for late 2022, pending FDA meeting outcomes.